单剂177Lu-PSMA-617后维持帕博利珠单抗治疗转移性去势抵抗性前列腺癌:开放标签、剂量扩展、1期试验
在转移性去势抵抗性前列腺癌患者中开展开放标签、剂量扩展1期试验,评估单剂177Lu-PSMA-617后维持帕博利珠单抗的安全性和活性。Part A确定推荐2期方案为177Lu-PSMA-617在帕博利珠单抗开始前28天给药;Part B中25例患者确认客观缓解率为56%(95%CI 35-76)。43例中2例(5%)发生≥3级治疗相关不良事件,无治疗相关死亡。
要点
- Part A确定推荐2期方案为单剂177Lu-PSMA-617 7.4 GBq在帕博利珠单抗开始前28天静脉给药。
- Part B中25例患者确认客观缓解率为56%(95%CI 35-76)。
- 43例中2例(5%)发生≥3级治疗相关不良事件,无治疗相关死亡。
核心结论
- 单剂177Lu-PSMA-617启动后维持帕博利珠单抗在转移性去势抵抗性前列腺癌患者中安全,并具有令人鼓舞的初步活性。
研究设计与样本
- 开放标签、剂量扩展、1期研究,在美国加利福尼亚大学旧金山分校开展。
- 纳入年龄≥18岁、ECOG体能状态0或1、一种或以上雄激素信号抑制剂治疗进展、68Ga-PSMA-11 PET显示至少3个PSMA avid病灶的转移性去势抵抗性前列腺癌男性患者。
- Part A患者序贯入组3种方案之一:单剂177Lu-PSMA-617 7.4 GBq静脉给药分别于维持帕博利珠单抗(200 mg每3周静脉给药)开始前28天(方案1)、同时(方案2)或开始后21天(方案3)。
- Part B采用推荐2期方案入组25例患者;分析集包括所有接受至少一剂帕博利珠单抗或177Lu-PSMA-617的患者。
- 2019年8月8日至2022年5月7日共入组43例男性患者(Part A 18例,每方案6例;Part B 25例),中位随访16.5个月(IQR 12.2-21.9)。
主要发现
- Part A基于安全性和给药可行性选择方案1作为Part B的推荐2期方案。
- Part B中25例患者有14例(56%;95%CI 35-76)达到确认客观缓解。
- 43例患者中2例(5%)发生≥3级治疗相关不良事件(方案2中1例3级关节炎,方案3中1例3级肺炎)。
- 观察到1例严重不良事件(1例因吸入性肺炎死亡),无治疗相关死亡。
关键数值与推荐
- 推荐2期方案为单剂177Lu-PSMA-617 7.4 GBq静脉给药于帕博利珠单抗(200 mg每3周静脉给药)开始前28天。
- Part B确认客观缓解率为56%(95%CI 35-76,14/25)。
- ≥3级治疗相关不良事件发生率为5%(2/43)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether a single dose of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-617 (177Lu-PSMA-617) followed by maintenance pembrolizumab was safe and could induce durable clinical benefit. METHODS: We did an open-label, dose-expansion, phase 1 study at the University of California, San Francisco (San Fransisco, CA, USA). Eligible patients were men aged 18 years or older with progressive metastatic castration-resistant prostate cancer who had an Eastern Cooperative Oncology Group performance status of 0 or 1, had progression on one or more androgen signalling inhibitors, and at least three PSMA-avid lesions on 68Ga-PSMA-11 positron emission tomography. In part A, patients were enrolled sequentially to one of three schedules in which a single dose of 177Lu-PSMA-617 (7·4 GBq) was given intravenously 28 days before (schedule 1), concomitant with (schedule 2), or 21 days after (schedule 3) the start of maintenance intravenous pembrolizumab (200 mg every 3 weeks). In part B, 25 patients were enrolled using the recommended phase 2 schedule. The primary endpoint in part A was determination of the recommended phase 2 schedule, and in part B, the objective response rate. The analysis set included all patients who received at least one dose of pembrolizumab or 177Lu-PSMA-617. This study is registered with ClinicalTrials.gov, NCT03805594. FINDINGS: Between Aug 8, 2019 and May 7, 2022, 43 male patients were enrolled (n=18 part A [six patients per schedule]; n=25 part B), with a median follow-up of 16·5 months (IQR 12·2-21·9). Schedule 1 was selected as the recommended phase 2 schedule for part B, on the basis of safety and feasibility of administration observed in part A. In part B, 14 (56%; 95% CI 35-76) of 25 patients had a confirmed objective response. Two (5%) of 43 patients had a treatment-related adverse event of grade 3 or worse (grade 3 arthritis in schedule 2, grade 3 pneumonitis in schedule 3). One serious adverse event (one death due to aspiration pneumonia) and no treatment-related deaths were observed. INTERPRETATION: A single priming dose of 177Lu-PSMA-617 followed by pembrolizumab maintenance was safe and had encouraging preliminary activity in patients with metastatic castration-resistant prostate cancer. FUNDING: Prostate Cancer Foundation, National Cancer Institute, Novartis Pharmaceuticals, and Merck.
引用
- Aggarwal R, Starzinski S, de Kouchkovsky I, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023. PMID: 37922930. doi:10.1016/S1470-2045(23)00451-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。